STOCK TITAN

NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31st Annual Healthcare Conference. Both virtual investor conferences take place in March 2021.

Conference Details:
Event:H.C. Wainwright Global Life Sciences Conference
Date:Tuesday, March 9th   
Time:7:00 a.m. ET
Location:Webcast Link – or at the company’s website (click here)
  
  
Event:Oppenheimer 31st Annual Healthcare Conference
Date:Wednesday, March 17th   
Time:11:20 a.m. ET
Location:Webcast Link – or at the company’s website (click here)

The webcasts from both conferences will also be archived on the NeuBase website, www.neubasetherapeutics.com.

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase's designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366


NeuBase Therapeutics, Inc.

NASDAQ:NBSE

NBSE Rankings

NBSE Latest News

NBSE Stock Data

1.52M
3.30M
13.38%
12.68%
4%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PITTSBURGH

About NBSE

neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.